An Organoid-based Functional Precision Medicine Trial in Osteosarcoma

Launched by JONSSON COMPREHENSIVE CANCER CENTER · Sep 26, 2023

Keywords

ClinConnect Summary

This clinical trial, called "An Organoid-based Functional Precision Medicine Trial in Osteosarcoma," is focused on understanding how patients with osteosarcoma, a type of bone cancer, might respond to different chemotherapy treatments. The researchers aim to use small samples of the tumor, obtained during routine biopsies or surgeries, to see how these cancer cells behave in the lab. By doing this, they hope to identify which chemotherapy drugs are most likely to work for each patient, based on how their specific cancer cells react. Additionally, the study will look at the genetic makeup of the tumors to gain more insights into osteosarcoma.

If you are considering participating in this trial, you may be eligible if you have imaging results that suggest osteosarcoma and are scheduled for a biopsy or surgery to confirm the diagnosis. This trial is open to all genders and is currently recruiting participants. Those involved can expect to contribute to important research that may help improve treatment options for future patients with osteosarcoma, while also receiving additional information about their own tumor's characteristics.

Gender

ALL

Eligibility criteria

• Inclusion / exclusion criteria - Group1:
• • - Patients without diagnosis of osteosarcoma and whose imaging studies are suggestive of osteosarcoma and who are planned to undergo biopsy or surgery for diagnostic purposes
• Inclusion / exclusion criteria - Group 2:
• • - Patients whose imaging studies are suggestive of metastatic osteosarcoma and who are planned to undergo biopsy or surgery for diagnostic purposes